Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018
The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02602938 (Aspirin on CTCs of Advanced Breast and Colorectal Cancer), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Aspirin on CTCs of Advanced Breast and Colorectal Cancer
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Effects of enoxaparin and aspirin on metastatic spread in a murine melanoma model.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Healing dynamics and surgery in breast cancer: rethinking a timeless challenge in light of advancing therapies and technologies.Journal of translational medicine · 2026Review
- Individualized treatment of HER2-positive breast cancer patients with lung metastasis using a circulating tumor cell drug sensitivity test: a case report.Frontiers in oncology · 2026Article
- Unveiling the "Dark Matter" of platelet involvement in tumor microenvironment.Journal of pharmaceutical analysis · 2025Review
- Clinical applications of circulating tumor cells in metastasis and therapy.Journal of hematology & oncology · 2025Review
- New insights into the correlations between circulating tumor cells and target organ metastasis.Signal transduction and targeted therapy · 2023Review
- The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer.World journal of surgical oncology · 2023Article
- Colorectal cancer chemoprevention: is aspirin still in the game?Cancer biology & therapy · 2022Review
- Article
- Ezrin expression in circulating tumor cells is a predictor of prostate cancer metastasis.Bioengineered · 2022Article
- Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong: A cohort study.PLoS medicine · 2022Article
- Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer.Translational lung cancer research · 2021Review
- (Im)maturity in Tumor Ecosystem.Frontiers in oncology · 2021Review
- New Formulation of a Methylseleno-Aspirin Analog with Anticancer Activity towards Colon Cancer.International journal of molecular sciences · 2020Article
- Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer.Cancer medicine · 2020Article
- Platelets and Metastasis: New Implications of an Old Interplay.Frontiers in oncology · 2020Review
- The current status of the clinical utility of liquid biopsies in cancer.Expert review of molecular diagnostics · 2019Review
- Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment.Cells · 2019Review
- Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases.Cancer metastasis reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
purposeAspirin could reduce the risk of cancer metastasis. Circulating tumor cells (CTCs) are a key factor of cancer metastasis, but no evidence has revealed how aspirin affects CTCs and its epithelial-mesenchymal transition (EMT). Here, we conducted a clinical trial to investigate how aspirin affects CTCs in metastatic colorectal cancer (MCC) and breast cancer patients (MBC).
methodsThe trial is retrospective registered at clinicaltrials.gov (NCT02602938). The eligible patients are given 100 mg aspirin q.d. for 8 weeks, and CTCs are evaluated at baseline, 4 and 8 weeks for absolute number, phenotype (epithelial type, E+, mesenchymal type, M+, and biophenotypic type, B+), and vimentin expression.
resultsData on 21 MCC and 19 MBC patients are analyzed, and it revealed that the CTC numbers decreased with aspirin treatment in MCC (p < 0.001) but not MBC (p = 0.0532); besides, ratio of E+ CTCs increased (p = 0.037) and M+ CTCs decreased at 2 months in MCC (p = 0.013), but neither the ratio of E+ or M+ CTCs changes significantly in MBC; vimentin expression of M+ CTCs is higher than E+ and B+ CTCs either in MBC or MCC patients at baseline (p < 0.01); and aspirin suppresses the vimentin expression in M+ (p = 0.002)and B+ (p = 0.006) CTCs of MCC and M+ CTCs of MBC (p = 0.004); besides it find vimentin expression in B+ (p = 0.004) or M+ (p < 0.001), CTCs are markedly decreased in patients with total CTC numbers declined.
conclusionAspirin could decrease CTCs numbers and block EMT transition in MCC patients and part of MBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.